Skip to main content
medRxiv
  • Home
  • About
  • Submit
  • ALERTS / RSS
Advanced Search

Antibody response to SARS-CoV-2 infection in humans: a systematic review

Nathan Post, Danielle Eddy, Catherine Huntley, May C. I. van Schalkwyk, Madhumita Shrotri, David Leeman, Samuel Rigby, Sarah V. Williams, William H. Bermingham, Paul Kellam, John Maher, Adrian M. Shields, Gayatri Amirthalingam, Sharon J. Peacock, Sharif A. Ismail
doi: https://doi.org/10.1101/2020.08.25.20178806
Nathan Post
1Faculty of Public Health and Policy, London School of Hygiene and Tropical Medicine, UK
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Danielle Eddy
2National Infection Service, Public Health England, UK
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • For correspondence: danielle.eddy2@nhs.net
Catherine Huntley
1Faculty of Public Health and Policy, London School of Hygiene and Tropical Medicine, UK
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
May C. I. van Schalkwyk
3Department of Public Health, Environments and Society, London School of Hygiene and Tropical Medicine, UK
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Madhumita Shrotri
1Faculty of Public Health and Policy, London School of Hygiene and Tropical Medicine, UK
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
David Leeman
2National Infection Service, Public Health England, UK
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Samuel Rigby
1Faculty of Public Health and Policy, London School of Hygiene and Tropical Medicine, UK
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Sarah V. Williams
1Faculty of Public Health and Policy, London School of Hygiene and Tropical Medicine, UK
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
William H. Bermingham
4Department of Clinical Immunology, University Hospitals Birmingham, UK
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Paul Kellam
5Department of Infectious Disease, Faculty of Medicine, Imperial College London, UK
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
John Maher
6School of Cancer and Pharmaceutical Studies, King’s College London, UK
7Department of Immunology, Eastbourne Hospital, UK
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Adrian M. Shields
8Clinical Immunology Service, Institute of Immunology and Immunotherapy, University of Birmingham, UK
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Gayatri Amirthalingam
2National Infection Service, Public Health England, UK
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Sharon J. Peacock
2National Infection Service, Public Health England, UK
9Department of Medicine, University of Cambridge, UK
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Sharif A. Ismail
2National Infection Service, Public Health England, UK
10Department of Global Health and Development, London School of Hygiene and Tropical Medicine, UK
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Abstract
  • Full Text
  • Info/History
  • Metrics
  • Supplementary material
  • Data/Code
  • Preview PDF
Loading

ABSTRACT

Introduction Progress in characterising the humoral immune response to Severe Acute Respiratory Syndrome 2 (SARS-CoV-2) has been rapid but areas of uncertainty persist. This review comprehensively evaluated evidence describing the antibody response to SARS-CoV-2 published from 01/01/2020-26/06/2020.

Methods Systematic review. Keyword-structured searches were carried out in MEDLINE, Embase and COVID-19 Primer. Articles were independently screened on title, abstract and full text by two researchers, with arbitration of disagreements. Data were double-extracted into a pre-designed template, and studies critically appraised using a modified version of the MetaQAT tool, with resolution of disagreements by consensus. Findings were narratively synthesised.

Results 150 papers were included. Most studies (75%) were observational in design, and included papers were generally of moderate quality based on hospitalised patients. Few considered mild or asymptomatic infection. Antibody dynamics were well described in the acute phase, and up to around 3 months from disease onset, although inconsistencies remain concerning clinical correlates. Development of neutralising antibodies following SARS-CoV-2 infection is typical, although titres may be low. Specific and potent neutralising antibodies have been isolated from convalescent plasma. Cross reactivity but limited cross neutralisation occurs with other HCoVs. Evidence for protective immunity in vivo is limited to small, short-term animal studies, which show promising initial results in the immediate recovery phase.

Interpretation Published literature on immune responses to SARS-CoV-2 is of variable quality with considerable heterogeneity with regard to methods, study participants, outcomes measured and assays used. Antibody dynamics have been evaluated thoroughly in the acute phase but longer follow up and a comprehensive assessment of the role of demographic characteristics and disease severity is needed. The role of protective neutralising antibodies is emerging, with implications for therapeutics and vaccines. Large, cross-national cohort studies using appropriate statistical analysis and standardised serological assays and clinical classifications should be prioritised.

Competing Interest Statement

John Maher is chief scientific officer, shareholder and scientific founder of Leucid Bio, a spinout company focused on development of cellular therapeutic agents. The authors report no other competing financial interests or conflicts of interest.

Clinical Protocols

https://www.crd.york.ac.uk/PROSPERO/display_record.php?RecordID=192528

Funding Statement

This research did not receive any specific grant from funding agencies in the public, commercial or not-for-profit sectors. MCIvS is funded by a NIHR Doctoral Fellowship (Ref NIHR300156). JM acknowledges the support of the National Institute for Health Research (NIHR) Biomedical Research Centre based at Guy's and St Thomas' NHS Foundation Trust and King's College London. SAI is supported by a Wellcome Trust Clinical Research Training Fellowship (Ref No 215654/Z/19/Z). The views expressed in this paper are those of the authors and not necessarily those of the NHS, the NIHR, PHE or the Department of Health.

Author Declarations

I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.

Yes

The details of the IRB/oversight body that provided approval or exemption for the research described are given below:

No ethical approval required as a systematic review

All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.

Yes

I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).

Yes

I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.

Yes

Data Availability

All data freely available via medical databases (Embase) and MedRxiv and BioRxiv

Copyright 
The copyright holder for this preprint is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. All rights reserved. No reuse allowed without permission.
Back to top
PreviousNext
Posted August 30, 2020.
Download PDF

Supplementary Material

Data/Code
Email

Thank you for your interest in spreading the word about medRxiv.

NOTE: Your email address is requested solely to identify you as the sender of this article.

Enter multiple addresses on separate lines or separate them with commas.
Antibody response to SARS-CoV-2 infection in humans: a systematic review
(Your Name) has forwarded a page to you from medRxiv
(Your Name) thought you would like to see this page from the medRxiv website.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Share
Antibody response to SARS-CoV-2 infection in humans: a systematic review
Nathan Post, Danielle Eddy, Catherine Huntley, May C. I. van Schalkwyk, Madhumita Shrotri, David Leeman, Samuel Rigby, Sarah V. Williams, William H. Bermingham, Paul Kellam, John Maher, Adrian M. Shields, Gayatri Amirthalingam, Sharon J. Peacock, Sharif A. Ismail
medRxiv 2020.08.25.20178806; doi: https://doi.org/10.1101/2020.08.25.20178806
Digg logo Reddit logo Twitter logo Facebook logo Google logo LinkedIn logo Mendeley logo
Citation Tools
Antibody response to SARS-CoV-2 infection in humans: a systematic review
Nathan Post, Danielle Eddy, Catherine Huntley, May C. I. van Schalkwyk, Madhumita Shrotri, David Leeman, Samuel Rigby, Sarah V. Williams, William H. Bermingham, Paul Kellam, John Maher, Adrian M. Shields, Gayatri Amirthalingam, Sharon J. Peacock, Sharif A. Ismail
medRxiv 2020.08.25.20178806; doi: https://doi.org/10.1101/2020.08.25.20178806

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Subject Area

  • Infectious Diseases (except HIV/AIDS)
Subject Areas
All Articles
  • Addiction Medicine (163)
  • Allergy and Immunology (416)
  • Anesthesia (92)
  • Cardiovascular Medicine (866)
  • Dentistry and Oral Medicine (159)
  • Dermatology (98)
  • Emergency Medicine (251)
  • Endocrinology (including Diabetes Mellitus and Metabolic Disease) (397)
  • Epidemiology (8588)
  • Forensic Medicine (4)
  • Gastroenterology (390)
  • Genetic and Genomic Medicine (1770)
  • Geriatric Medicine (169)
  • Health Economics (374)
  • Health Informatics (1251)
  • Health Policy (625)
  • Health Systems and Quality Improvement (472)
  • Hematology (197)
  • HIV/AIDS (380)
  • Infectious Diseases (except HIV/AIDS) (10340)
  • Intensive Care and Critical Care Medicine (553)
  • Medical Education (193)
  • Medical Ethics (51)
  • Nephrology (214)
  • Neurology (1692)
  • Nursing (97)
  • Nutrition (252)
  • Obstetrics and Gynecology (330)
  • Occupational and Environmental Health (451)
  • Oncology (931)
  • Ophthalmology (265)
  • Orthopedics (104)
  • Otolaryngology (172)
  • Pain Medicine (115)
  • Palliative Medicine (40)
  • Pathology (255)
  • Pediatrics (539)
  • Pharmacology and Therapeutics (256)
  • Primary Care Research (210)
  • Psychiatry and Clinical Psychology (1783)
  • Public and Global Health (3868)
  • Radiology and Imaging (627)
  • Rehabilitation Medicine and Physical Therapy (322)
  • Respiratory Medicine (525)
  • Rheumatology (208)
  • Sexual and Reproductive Health (170)
  • Sports Medicine (158)
  • Surgery (191)
  • Toxicology (36)
  • Transplantation (101)
  • Urology (76)